PS1470 EFFICACY AND SAFETY OF ANAGRELIDE IN OLDER PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Heinz Gisslinger(Medical University of Vienna), Siegfried Sormann(Medical University of Graz), Michael Steurer(Innsbruck Medical University), Bettina Gisslinger(Medical University of Vienna), Wolfgang Schimetta(Johannes Kepler University of Linz), J. Thiele, Günther Gastl(Innsbruck Medical University), Sonja Heibl(Klinikum Wels-Grieskirchen), Reinhard Ruckser(Donauspital), Maria Theresa Krauth(Medical University of Vienna), Ernst Forjan
HemaSphere
June 1, 2019
10.1097/01.hs9.0000564144.20696.4c
Cited by 0

Related Papers

Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)
|Blood|2012|596
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
|Blood|2011|448
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
|The Lancet Haematology|2020|351